Propanc Biopharma, Inc. (PPCB)
| Market Cap | 2.79M -87.5% |
| Revenue (ttm) | n/a |
| Net Income | -19.79M |
| EPS | -17.62 |
| Shares Out | 6.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 199,391 |
| Open | 0.4887 |
| Previous Close | 0.4857 |
| Day's Range | 0.4250 - 0.4899 |
| 52-Week Range | 0.4250 - 47.5000 |
| Beta | 3.33 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 16, 2026 |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the Univers... [Read more]
Financial Performance
Financial StatementsNews
Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma
Propanc Biopharma (PPCB) highlighted new preclinical data for its candidate PRP in pancreatic ductal adenocarcinoma and compared that profile with a clinical standard recently established by Revolutio...
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib
MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma files to sell 6.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 6.5M shares of common stock. The company is not selling any…
Propanc Biopharma Registration statement: Registration filing
Propanc Biopharma filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.
Propanc Biopharma FY26 EPS ($17.62)
“The Propanc Executive team are delighted with advancements made in the past financial year,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “The Company is poised to capitalize on the...
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
"The Company is poised to capitalize on the foundation set
Propanc Biopharma Annual report: Q4 2026
Propanc Biopharma has published its Q4 2026 annual report on September 25, 2026.
Propanc Biopharma issues comparative analysis of PRP versus ERAS-0015
Propanc Biopharma (PPCB) issued a comparative analysis of lead candidate PRP against recently reported clinical datasets from Erasca’s pan-RAS molecular glue ERAS-0015 in pancreatic ductal adenocarcin...
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015 Datase...
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chr...
Propanc Biopharma to commence first-in-human study of PRP in February
Propanc Biopharma (PPCB) announced plans to commence a Phase 1b first-in-human study of PRP in February 2027. The multicenter, open-label study will enroll up to 50 patients with advanced solid…
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chr...
Why Is Penny Stock Propanc Biopharma (PPCB) Up 245% Today?
Propanc Biopharma stock experienced a massive rally on Thursday alongside early cancer treatment test results.
Propanc Biopharma announces new preclinical data for PRP in PDAC
Propanc Biopharma (PPCB) announced new preclinical and early translational data for PRP in pancreatic ductal adenocarcinoma, or PDAC. In orthotopic and patient-derived xenograft models of advanced PDA...
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma starts finalization of clinical trial protocol for PRP study
Propanc Biopharma (PPCB) announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its first-in-human, Phase 1b clinical study of PRP in up…
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc highlights PRP as potential therapy against RAS-driven cancers
Propanc Biopharma (PPCB) provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines and Erasca. The company articulates why PRP’s mechanism, pr...
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread
Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma
Propanc Biopharma (PPCB) announced new preclinical and translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma, one of the most aggressive and treatment-resistant solid tumor...
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
MELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma registers to sell 2.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.5M shares of common stock. The company is not selling any…
Propanc Biopharma Registration statement: Registration filing
Propanc Biopharma filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.